Sarah E. M. Herman

National Institutes of Health — United States

Medicine · Health Sciences

26h-index4.4kcitations94works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(89), Lymphoma Diagnosis and Treatment(54), Immunodeficiency and Autoimmune Disorders(17), Galectins and Cancer Biology(16), Chronic Myeloid Leukemia Treatments(15)

Publications94 total

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Blood·2025· 2 citedOpen Access
Data from Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
2023Open Access
Supplementary Figures S1-S10 from TLR Signaling Is Activated in Lymph Node–Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
2023Open Access
Supplementary Figure S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Data from The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Figure Legends from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Conflict of Interest Form from Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
2023Open Access
Supplementary Table S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Data from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table 1 from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
2023Open Access
Supplemental Table from The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Figure S1 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Figure S2 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table S1 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>
2023Open Access
Supplementary Table Descritptions from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Figure Legends from TLR Signaling Is Activated in Lymph Node–Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
2023Open Access
Supplementary methods and figure legends from Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
2023Open Access
Data from The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
2023Open Access
Data from TLR Signaling Is Activated in Lymph Node–Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
2023Open Access
Supplementary figures S1-S5 from Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Adrian Wiestner(47), Mohammed Farooqui(20), Clare Sun(15), Nakhle S. Saba(11), Carsten Utoft Niemann(11), Janet Valdez(10), Georg Aue(9), Gerald E. Marti(9), Stefania Pittaluga(9), Maryalice Stetler‐Stevenson(9), Inhye E. Ahn(9), Xin Tian(8), Susan Soto(8), Constance M. Yuan(8), Irina Marić(8), Delong Liu(8), Katherine R. Calvo(6), Rashida Z. Mustafa(6), Todd Covey(6), Raquel Izumi(6)